T0901317

Overview

T0901317 is an orally active and highly selective LXR agonist with an EC 50 of 20 nM for LXRα. T0901317 activates FXR with an EC 50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with K i values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > LXR | Products > Signaling Pathways > FXR | Products > Signaling Pathways > ROR | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-10626
• CAS No.: 293754-55-9
• Molecular Formula: C17H12F9NO3S
• Molecular Weight: 481.33
• Purity: 99.85%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 3 mg/mL (6.23 mM); Clear solution
• Availability: In-stock

Source

Original product source